Introduction Methylprednisolone acetate*has been administered intrathecally in more than 1,000 patients for the treatment of neurologic disorders¹⁻³during the last three years. The treatment has proved safe, and the results are encouraging. It has become a standard method of treatment for arachnoiditis resulting from trauma, Pantopaque, or laminectomy. With this new method of administration we thought it expedient to ascertain: first, how long methylprednisolone acetate remains in the cerebrospinal fluid after intrathecal administration; secondly, whether methylprednisolone acetate injected at the lumbar level is dispersed evenly throughout the subarachnoid space, or remains in a higher concentration at the site of injection, by analyzing fluids obtained simultaneously at lumbar and cisternal punctures; thirdly, the duration of action of the steroid as judged by the effect on endogenous secretion of corticosteroids; fourthly, the effect on spinal fluid pressure, protein and cell content of various amounts of methylprednisolone acetate. Methods, Procedures, and
No takes yet. Share an insight, caveat, or question.
Arjun D. Sehgal (1963) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: